Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Stuttgart - Delayed Quote EUR

Neuren Pharmaceuticals Ltd (NK9.SG)

6.25
+0.05
+(0.81%)
At close: April 25 at 8:04:04 AM GMT+2
Loading Chart for NK9.SG
  • Previous Close 6.20
  • Open 6.25
  • Bid 6.25 x --
  • Ask 6.60 x --
  • Day's Range 6.25 - 6.25
  • 52 Week Range 4.62 - 10.50
  • Volume 0
  • Avg. Volume 0
  • Market Cap (intraday) --
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date Feb 27, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Recent News: NK9.SG

View More

Performance Overview: NK9.SG

Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

NK9.SG
11.97%
S&P/ASX 200 [XJO] (^AXJO)
2.34%

1-Year Return

NK9.SG
37.19%
S&P/ASX 200 [XJO] (^AXJO)
3.71%

3-Year Return

NK9.SG
37.19%
S&P/ASX 200 [XJO] (^AXJO)
6.62%

5-Year Return

NK9.SG
37.19%
S&P/ASX 200 [XJO] (^AXJO)
51.99%

Compare To: NK9.SG

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NK9.SG

View More

Valuation Measures

Annual
As of 4/25/2025
  • Market Cap

    815.57M

  • Enterprise Value

    690.69M

  • Trailing P/E

    10.24

  • Forward P/E

    65.36

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.82

  • Price/Book (mrq)

    3.91

  • Enterprise Value/Revenue

    5.76

  • Enterprise Value/EBITDA

    7.00

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    --

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: NK9.SG

View More

Company Insights: NK9.SG

Research Reports: NK9.SG

View More